Dr.  Adam P. Dicker (Professor of Radiation Oncology) is the Director of the Division of Experimental Radiation Oncology in the Department of Radiation Oncology at Thomas Jefferson University.  He leads the Molecular Targets and Developmental Therapeutics Program at the Kimmel Cancer Center and is responsible for phase I trials with novels agents.

Dr. Dicker graduated from Columbia College and received his M.D. and Ph.D. from Cornell University Medical College.  He then completed an internship in Surgery at Lenox Hill Hospital and completed his residency in Department of Radiation Oncology at the Memorial Sloan-Kettering Cancer Center.

His laboratory research funded by the National Cancer Institute involves studying the role of the Epidermal Growth Factor Receptor (EGFR) and tumor microenvironment in solid tumors.  His research evaluates radiosensitization by EGFR blockade through an understanding of survival signals derived from extracellular matrix.  He currently is studying deregulated NF-kB signaling and its role in cancer biology.  Dr. Dicker’s other research effort builds on the use of zebrafish as a model organism to study molecular mechanisms of damage by radiation and chemotherapy.  Dr. Dicker’s laboratory program uses this model organism in conjunctional with nanotechnology drugs (nanoparticles) to identify novel radiation protectors/mitigators.

Dr. Dicker serves as the Vice Chair for Translational Research and Chair of the Translational Research Committee in the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cooperative group.  In addition, he is the principal investigator on a number of “first in man” clinical developmental therapeutic protocols involving novel signal transduction agents at Thomas Jefferson University.  Dr. Dicker is Chair of the ASTRO Radiation Biology and Cancer Committee and also serves as a member of the Corporate Relations Committee.

Dr. Dicker is a board certified radiation oncologist.  Among other honors, he has received an American Cancer Society Fellowship and an ASTRO/ESTRO Travel Grant.

Dr. Alexander Lin (Assistant Professor of Radiation Oncology) is a graduate of Yale University and the University of Michigan Medical School. He completed his Radiation Oncology residency at the University of Michigan, where he served as Chief Resident.

Dr. Lin is an active member of several professional societies including ASCO and ASTRO. His areas of interest and expertise include gastrointestinal and genitourinary malignancies. He has published and presented on a variety of clinical oncology topics.

Dr. Mitchell Machtay , is the Walter J. Curran Jr., M.D., Associate Professor and Vice Chairman of The Department of Radiation Oncology.  Dr. Machtay is a graduate of Princeton University and The New York University School of Medicine.  He completed his Radiation Oncology residency at the University of Pennsylvania, where he served as Chief Resident.   He was an attending physician in radiation oncology at the Hospital of the University of Pennsylvania since 1993, where he was promoted to Associate Professor in the year 2002. 

Dr. Machtay has received the Giulio D’Angio Award for Teaching Excellence in the Department of Radiation Oncology in July 1996, and the ARRO (Association of Residents in Radiation Oncology) “Teacher of the Year Award” for the Year 2000.  He currently holds the position of deputy chair of Radiation Therapy Oncology Group (RTOG). His areas of interest and expertise include head and neck cancer, lung cancer and tumors within or near the central nervous system, where highly conformal radiation techniques are particularly useful. He has published and presented extensively on a variety of clinical oncology topics.